|
Marinomed Biotech AG / Key word(s): Strategic Company Decision Marinomed Biotech AG evaluates strategic options for Carragelose portfolio 18-Dec-2023 / 08:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) announces that the Company considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. The Company is continuously evaluating the business to enable the best possible future growth. Regulatory changes in the coming year will also be included in the evaluation, which are expected to have a positive impact on the Company’s business, particularly with regard to Carragelose products. The evaluation process may include strategic partnerships and the consideration of transferring the Carragelose portfolio to a partner that could maximize its value enabling the Company to increase its focus on the Marinosolv platform. +++ End of the ad hoc announcement +++ End of Inside Information 18-Dec-2023 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Study shows clear benefit from COVID-19 vaccination for heart failure patients
Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research
May 13, 2024